Health Canada Approves Diovan (valsartan) to reduce cardiovascular death after heart failure

... Novartis Pharmaceuticals Canada Inc. announced today that Health Canada has approved PrDiovan* (valsartan) for a new indication to reduce cardiovascular death in patients at high risk (with heart failure or left ventricular dysfunction) following a heart attack. Diovan* is the world''s most prescribed angiotensin-receptor blocker (ARB) for mild-to-moderate hypertension... click link for more info. ...